ClinicalTrials.gg
TerminatedNCT05865561ICONEUpdated Oct 7, 2026

Identification of Volatile Organic Compounds (VOCs) as Biopredictors of Epileptic Seizures

An observational study in Epilepsy, sponsored by Fondation Ophtalmologique Adolphe de Rothschild. Terminated at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Fondation Ophtalmologique Adolphe de Rothschild · Observational

How we know

Why this study was terminated
Insufficient enrollement of patients
Updated Oct 7, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
45
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Epilepsy by Fondation Ophtalmologique Adolphe de Rothschild — 7 open to participants now, 7 under way, none of them phase 3. Epilepsy · Fondation Ophtalmologique Adolphe de Rothschild.

Started
2024
the only one that year
Observational
7 of 10
5 open now
Registered
6th of 10
by date

Among the 10 studies in Epilepsy by Fondation Ophtalmologique Adolphe de Rothschild, this one is the only one that started in 2024, is one of 7 observational ones, and was the 6th registered.

Epilepsy

1,850 studies on the registry are indexed under Epilepsy; 418 are open to participants now.

Browse Epilepsy studies →

Open to participants now

7 of the 10 studies in Epilepsy by Fondation Ophtalmologique Adolphe de Rothschild are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 284 Epilepsy studies recruiting now, 113 (40%) set no upper age limit and 148 (52%) stop at 75 or younger; 138 take children under 18; 54 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Epilepsy by Fondation Ophtalmologique Adolphe de Rothschild, or all of them as a file.
02

Study summary

The unpredictable nature of epileptic seizures places people with epilepsy under permanent psychological stress, which contributes significantly to a restriction in their quality of life. The possibility of predicting the arrival of epileptic seizures would allow, in addition to taking a preventive treatment if the risk of seizure is close, to prevent traumas and accidents linked to possible falls during seizures, to authorize driving for certain people with epilepsy and to reduce the costs of medical care. To date and to our knowledge, no seizure detection device has been commercialized. There are commercialized devices based on biometric sensors other than EEG, but these are strictly dedicated to the detection of seizures and do not allow the anticipation of seizures. Regarding prediction, current research seems to have difficulties in developing convincing algorithms. The only system used successfully in real time would require a device implantable in the brain, but this would raise problems of acceptability.

In addition, 20% of people with drug-resistant epilepsy have psychogenic non-epileptic seizures (PNES). These are sometimes difficult to differentiate from epileptic seizures by people with epilepsy and their caregivers, and their management differs from that of epileptic seizures. The distinction between these 2 types of events should also be taken into account by these prediction/detection tools.

From the field of biomedical detection dogs, there is currently a converging body of evidence supporting that people with epilepsy emit specific odors associated with seizure events. Trained dogs have been shown to be able to discriminate body odors sampled during or just after an epileptic seizure from those sampled from the same subjects in various contexts outside of a seizure. It was also shown that a seizure can also be predicted by the volatile organic compounds (VOCs) released by the patient (human volatilome); the olfactory signature being already detectable up to 3h before a seizure. Another study used trained dogs to confirm that they are able to detect a seizure by smell and that this olfactory difference is already detectable before a seizure.

The human volatilome VOCs lead is particularly promising, notably for its non-invasiveness and for the pre-ictal precocity that prediction allows. But at the moment, the studies are too studies are too preliminary, with sample sizes too small to conclude on the inter-individual generalization of the odor, taking into account the type of seizure involved and the influence of other variables (e.g., gender, age, medications). Moreover, in order to develop a reliable and transportable electronic detection tool, the identification of the VOCs involved is necessary, since the choice of sensors (e.g., to constitute an electronic nose) depends on it. The objective of this study is to overcome these shortcomings, by aiming at the identification of the informative odor(s) associated with epileptic events during the pre-ictal, ictal and post-ictal periods, taking into account the type of seizures (focal seizures, secondary generalized focal seizures, primary generalized seizures - motor and non-motor) and the inter-individual differences.

03

Conditions studied

  • Epilepsy

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

The epileptics will be recruited by the neurologists from among the epileptics treated at the Institut la Teppe and the Fondation A de Rothschild Hospital who meet the selection criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Person at least 18 years of age
  • With drug-resistant epilepsy according to the ILAE criteria
  • With one of the following 3 types of seizures :

Focal seizures Focal seizures with secondary generalization Generalized seizures - motor or non-motor

  • Requiring at least 48 hours of video-EEG
  • Consent to participate in the study from the patient and his/her legal guardian, if applicable
  • Affiliated or beneficiary of a social security plan

Exclusion criteria

Exclusion Criteria:

  • Person with epilepsy benefiting from a legal protection measure other than curatorship or guardianship
  • Pregnant or breastfeeding woman
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
45 participants (actual)
Patient registry
No

Interventions

  • OtherVOC sampling

    * Continuous systematic sampling at HFAR: Samples every 3 hours (3 a.m., 6 a.m., 9 a.m., 12 p.m., 3 p.m., 6 p.m., 9 p.m., midnight) until the end of the monitoring period. * Systematic sampling during the day: Samples every 3 hours at Institut La TEPPE (9am, 12pm, 3pm, 6pm, 9pm) until the end of the follow-up period. * Sampling in case of epileptic seizure : Sampling during the seizure (from t0 to t+5 min), whatever the time. The samples will be taken using a compress on the forehead, the palms of the hands and the back of the neck. The compress will then be placed in a freezer bag and the person with epilepsy will be asked to exhale into the bag, if he/she is able to do so, before closing it.

06

What researchers measure

Primary outcomes

  1. Identification of human volatile organic compounds (VOCs) biopredictors of epileptic seizures.

    Distribution of molecules or pieces of molecules per sample.

    Time frame: Day 0

07

Study locations

2 sites
  • Hôpital Fondation Adolphe de Rothschild
    Paris, 75019, France
  • Institut La Teppe
    Tain-l'Hermitage, 26600, France
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Feb 2024 to primary completion in May 2026, 27 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 7, 2026: primary completion Jun 2026 → May 2026 and completion Jun 2026 → May 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2023
First posted
May 19, 2023
StartActual
Feb 3, 2024
Primary completionActual
May 29, 2026was Jun 2026
CompletionActual
May 29, 2026was Jun 2026
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated Insufficient enrollement of patients
changed Oct 7, 2026
Primary completion
Jun 24, 2026→May 29, 2026 (actual)
Oct 7, 2026
Study completion
Jun 24, 2026→May 29, 2026 (actual)
Oct 7, 2026
Enrollment
100 (estimated)→45 (actual)
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Recruiting→Terminated
    Why stopped Insufficient enrollement of patients
    Primary completion Jun 24, 2026→May 29, 2026 (now actual)
    Study completion Jun 24, 2026→May 29, 2026 (now actual)
    Enrollment 100 (estimated)→45 (actual)
    + 3 other changes: verification date, site details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05865561
Responsible party
Sponsor
First posted
May 19, 2023
Start date
Feb 3, 2024
Primary completion
May 29, 2026
Completion
May 29, 2026
Last update
Oct 7, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion